Product Description: Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis[1].
Applications: Metabolism-protein/nucleotide metabolism
Formula: N/A
References: [1]Lee JW, et, al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019 Feb 7;133(6):530-539.
CAS Number: 1803171-55-2
Molecular Weight: N/A
Compound Purity: 95.00
Research Area: Metabolic Disease
Solubility: H2O
Target: Complement System